SEC Form 4 · accession 0001437749-26-029196
Eton Pharmaceuticals, Inc. · ETON
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Paul V Maier
Director
Period of report
Aug 28, 2026
Accepted (ET)
Aug 28, 2026 · 4:51 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001710340
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 28, 2026 | M | 50,000 | $3.78 | A | 109,745 | D | |
| Common StockF1,F2 | Aug 28, 2026 | S | 36,387 | $58.64 | D | 73,358 | D | |
| Common StockF1,F4 | Aug 28, 2026 | S | 13,485 | $60.21 | D | 59,873 | D | |
| Common StockF1,F5 | Aug 28, 2026 | S | 128 | $61.77 | D | 59,745 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock OptionF3 | $3.78 | Aug 28, 2026 | M | 50,000 | D | Feb 7, 2022 | Feb 6, 2032 | Common Stock | 50,000 | 0 | D |
Explanation of responses
- F1The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
- F2The shares were sold in multiple trades at prices ranging from $58.50 to $58.97. The price reported above reflects the weighted average sales price.
- F3The shares subject to the option vested in 48 equal monthly installments from the date of grant (2-07-2022) until fully vested.
- F4The shares were sold in multiple trades at prices ranging from $60.00 to $61.00. The price reported above reflects the weighted average sales price.
- F5The shares were sold in multiple trades at prices ranging from $61.10 to $61.98. The price reported above reflects the weighted average sales price.
Remarks
The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for indefinite duration.